abstract: Increasingly, placental DNA methylation is assessed as a factor in pregnancy-related complications, yet the transcriptional impact of such findings is not always clear. Using a proliferative in vitro placental model, the effect of DNA methylation loss on gene activation was evaluated at a number of genes selected for being differentially methylated in pre-eclampsia-associated placentae in vivo. We aimed to determine whether reduced DNA methylation at specific loci was associated with transcriptional changes at the corresponding gene, thus providing mechanistic underpinnings for previous clinical findings and to assess the degree of transcriptional response amongst our candidate genes. BeWo and JEG3 choriocarcinoma cells were exposed to 1 mM 5-Aza-2 ′ -deoxycytidine (5-Aza-CdR) or vehicle control for 48 h, and re-plated and cultured for a further 72 h in normal media before cells were harvested for RNA and DNA. Bisulphite pyrosequencing confirmed that DNA methylation was reduced by 30 -50% points at the selected loci studied in both cell lines. Gene activation, measured by qRT-PCR, was highly variable and transcript specific, indicating differential sensitivity to DNA methylation. Most notably, loss of DNA methylation at the leptin (LEP) promoter corresponded to a 200-fold and 40-fold increase in LEP expression in BeWo and JEG3 cells, respectively (P , 0.01). Transcripts of steroidogenic pathway enzymes CYP11A1 and HSD3B1 were up-regulated 40-fold in response to 5-Aza-CdR exposure in BeWo cells (P , 0.01). Other transcripts, including aromatase (CYP19), HSD11B2, inhibin (INHBA) and glucocorticoid receptor (NR3C1) were more moderately, although significantly, affected by loss of associated DNA methylation. These data present a mixed effect of DNA methylation changes at selected loci supporting cautionary interpretation of DNA methylation results in the absence of functional data.
Introduction
Pre-eclampsia, a serious hypertensive disorder in pregnancy, arises through compromised placental function and continues to be one of the highest causes of maternal morbidity (Lewis, 2003 ), yet the underlying aetiology remains to be fully elucidated (Roberts and Bell, 2013) . Pre-eclampsia is associated with the placental perturbation of a number of key gene pathways related to endothelial dysfunction, angiogenesis, apoptosis, inflammation, hypoxia and stress signalling (Enquobahrie et al., 2008; Hoegh et al., 2010; Nishizawa et al., 2011; Tsai et al., 2011) . Placental DNA methylation profiling has also revealed genome-wide disturbance of epigenetic marks in pre-eclampsia (Yuen et al., 2010; Blair et al., 2013) . In addition, using candidate gene approaches we have previously demonstrated that placental DNA methylation is altered at loci related to steroid hormonal synthesis, stress hormone signalling and bioavailability (Hogg et al., 2013a) and peptide hormone production (Hogg et al., 2013b) in pregnancies affected by pre-eclampsia.
In addition to epigenetic studies in specific pregnancy complications, DNA methylation is now widely studied in the context of health and disease, and particularly in the early life programming of child and adult wellbeing (Perera and Herbstman, 2011; Hogg et al., 2012) . While many studies have retrospectively focused on individuals exposed to unfavourable maternal or post-natal environments through DNA methylation analysis of whole blood (Tobi et al., 2009; Radtke et al., 2011) , cord blood (Oberlander et al., 2008; Perroud et al., 2011) , buccal epithelium (Breton et al., 2009 ) and post-mortem tissue (McGowan et al., 2009) , fewer have studied the role of the placenta in mediating the epigenetic † Joint senior author.
programming effects of an adverse environment to the fetus (Hogg et al., 2012; Koukoura et al., 2012) .
Moreover, despite the fact that many changes in DNA methylation are described in studies of fetal programming and/or that of specific pregnancy complications such as pre-eclampsia, it is not entirely clear whether altered DNA methylation can be directly linked to gene expression at these genomic regions in the tissue of interest. While it is commonly perceived that CpG-rich promoter methylation is inversely related to the tissue-specific expression of the associated transcript (Song et al., 2005) , this is not true for all differentially methylated loci (Walsh and Bestor 1999; Bird 2002; Weber et al., 2005) . It is now apparent that DNA methylation at coding and non-coding regions downstream of the transcription start site, within CpG island 'shores' and proximal to enhancer regions that lie at distal upstream regions, may also be of regulatory importance (Jones 2012; Shenker and Flanagan 2012) . Furthermore, the placenta exhibits a unique DNA methylation profile (Schroeder et al., 2013) , including overall reduced methylation compared with somatic tissues, which questions whether DNA methylation is as important a regulator of gene expression in the placenta as in somatic tissues.
Using candidate genes previously shown to have altered DNA methylation patterns in pre-eclampsia, we investigated the in vitro effect of global DNA methylation knock-down, using a DNA methyltransferase 1 (DNMT1) inhibitor, 5-Aza-2 ′ -deoxycytidine (5-Aza-CdR), in two trophoblast-derived choriocarcinoma cell lines. These included BeWo cells, which possess a molecular phenotype characteristic of cytotrophoblast cells (Grümmer et al., 1990) , and JEG3 cells, which morphologically and functionally resemble extravillous trophoblasts (Grümmer et al., 1994) . The inclusion of the two cell lines was chosen to provide a more representative and complete assessment of DNA methylation knock-down in cells originating from differing placental cell types.
Herein, we present a mixed effect of widespread DNA methylation loss in these placental-derived cell types, with highly variable gene expression responses to altered DNA methylation profiles.
Materials and Methods

Trophoblast-derived cell line culture
Two trophoblast-derived choriocarcinoma cell lines, BeWo (Pattillo and Gey, 1968) and JEG3 (Kohler and Bridson, 1971 ) cells, were used as a model to study the effect of global DNA methylation knock-down. The advantages of using these cell lines over primary cytotrophoblasts is that they can replicate in culture with little or no differentiation, a requirement for the 5-aza-Cdr treatments being utilized. BeWo cells (B30 clone, which do fuse upon treatment with forskolin or cAMP; CCL-98) were kindly gifted by Jerome Strauss III and JEG3 (HTB-36) cells were obtained from the American Type Culture Collection. BeWo cells were maintained in Ham's F12K (Kaighn's) medium containing 2 mM L-glutamine and 0.007 mM phenol red (Invitrogen, Carlsbad, CA, USA), 10% fetal bovine serum (FBS; Invitrogen) and 100 U/ml penicillin/streptomycin (P/S; Invitrogen). JEG3 cells were maintained in Dulbecco's modified eagle medium (DMEM) containing 25 mM D-glucose, 4 mM L-glutamine and 0.03 mM phenol red (Invitrogen), 10% FBS and 100 U/ml P/S. For treatment experiments, BeWo and JEG3 cells were plated at 1.25 -1.50 × 10 6 cells/10 cm plastic dish in either Ham's F12K medium (BeWo) or DMEM without phenol red (JEG3; Invitrogen). Both media contained 10% charcoal-stripped FBS (Invitrogen) and 100 U/ml P/S. Cells were incubated overnight at 378C/ 5% CO 2 to reach 20 -30% confluency.
Determination of differentiation potential of BeWo cells
Since BeWo cells can spontaneously fuse in culture over time, and to ensure that any changes in DNA methylation were due to the 5-Aza-Cdr model, and not a consequence of the culture period itself, the fusion and differentiation phenotype of BeWo cells over the course of 3 days was assessed. BeWo cells were treated at 0 h with +1 mM 8-bromoadenosine-3 ′ 5 ′ -cyclic monophosphate sodium salt (8-Br-cAMP; Sigma) in treatment media (n ¼ 3/group) and cultured at 378C/5% CO 2. RNA was extracted from cells at 48 and 72 h time points. Quantitative real-time (qRT) -PCR analyses were conducted for fusion markers GCM1 and ERVW1 (syncytin 1), expected to increase during syncytialization, and differentiation markers CGB5 (hCG) and CDH1 (E-cadherin), expected to increase and decrease, respectively, during syncytialization. While a syncytial phenotype was observed in BeWo cells exposed to the cAMP analogue (positive control), cells cultured under normal conditions presented an undifferentiated non-syncytial phenotype at 48 and 72 h similar to that at 0 h of culture (Supplementary data; Fig. S1 ).
5-Aza-CdR cell line treatments
During pilot studies, BeWo and JEG3 cells were treated with 1, 3, 5 or 10 mM 5-Aza-CdR (Sigma) or vehicle control at 0 h and cultured for 48 or 72 h at 378C/5% CO 2 (n ¼ 3/group). Treatment media were refreshed daily. Cells were subsequently re-plated and cultured for 72 h in untreated media, with one media change after 24 h to remove non-viable or dead cells. Cells were harvested and the resultant cell pellet was split for downstream DNA and RNA applications. Following preliminary analyses, the protocol was subsequently repeated in BeWo and JEG3 cells to include vehicle control and 1 mM 5-Aza-CdR treatments for 48 h to give n ¼ 6 independent experiments per cell line.
Cell viability assay
Cell viability experiments were performed in parallel with the above pilot studies. BeWo and JEG3 cells were plated in triplicate per time point and treatment dose at a density of 1000 cells per well in 96-well opaquewalled Nunclon plates (Fisher Scientific) and incubated overnight at 378C/5% CO 2 . At time 0, media containing 1, 3, 5 or 10 mM 5-Aza-CdR or vehicle control were added, and cells were incubated for 24, 48 or 72 h, with freshly prepared 5-Aza-CdR added daily. Cell viability at each time point was assessed using the CellTiter-Glo w Luminescent Cell Viability Assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Luminescent signal produced is directly proportional to the amount of ATP present and therefore a quantifiable measure of cell number.
DNA/RNA extraction DNA and RNA were each extracted from one-half of the cell pellet obtained for each 5-Aza-CdR treatment dose and duration. DNA was extracted using standard salting out methods and stored at 2208C. RNA was extracted using a standard phenol -chloroform protocol (Trizol; Invitrogen) and stored at 2808C. DNA and RNA concentrations and purities were quantified using the Nanodrop 1000 spectrophotometer (ThermoScientific, Waltham, MA, USA).
Bisulphite pyrosequencing
Bisulphite pyrosequencing was used to quantify DNA methylation at specific loci that we had previously identified as sites of differential DNA methylation in placentae associated with pre-eclampsia. Five hundred nanograms of DNA was subjected to bisulphite conversion using the EZ DNA methylation kit (Zymo Research Corp., Irvine, CA, USA). Pyrosequencing primers (forward, reverse and sequencing; Table I ) were designed using Pyro Q-CpG software (Qiagen Ltd, GmbH, Hilden, Germany). Forty nanograms of bisulphite converted DNA was PCR amplified in a 15 mL reaction volume consisting of 1× PCR buffer (Qiagen Ltd), 0.2 mM dNTPs (Invitrogen), 0.4 mM forward and reverse primers (Integrated DNA Technologies, Inc., Coralville, IA, USA) and 0.18 U DNA polymerase (HotStarTaq, Qiagen Ltd). PCR cycling consisted of 958C for 15 min, 40 cycles of 958C for 30 s, variable annealing temperature (Ta) for 30 s (Table I) , 728C for 30 s and finally 728C for 10 min. A long interspersed element 1 (LINE1) assay (Bollati et al., 2007) specific to a subset of LINE1 repeats (LINE1-H) of which there are 1200 copies present in the genome (Ewing and Kazazian, 2010) was included to obtain a genome-wide representation of the effect of 5-Aza-CdR exposure. PCR conditions for LINE1 consisted of 958C for 15 min, 45 cycles of 958C for 20 s, 508C for 20 s, 728C for 20 s and finally 728C for 5 min. PCR products were subjected to pyrosequencing using the Pyromark Q96 Pyrosequencer (Qiagen Ltd) following recommended protocols provided by the manufacturer. Within each cell type analysed, all samples were run on the same plate to avoid inter-plate variability and each assay included high and low methylation controls in addition to PCR and pyrosequencing blanks containing water instead of genomic material.
Quantitative real-time PCR
cDNA was synthesized from 300 ng RNA using the High Capacity cDNA Reverse Transcription kit (Invitrogen). Exon spanning primers (Table II) were designed in-house and validated using conventional PCR and gel electrophoresis to ensure a single product at the expected molecular weight. Primer pairs were subsequently validated for qRT-PCR using SYBR green chemistries, by generating a linear standard curve with an R 2 . 0.95 and slope between 23.3 and 23.5 per assay. qRT-PCR reactions consisted of 1× Fast SYBR Green master mix (Invitrogen), 0.5 mM primer pairs and 30 ng cDNA in a 10 mL reaction volume. Per assay, samples were run in duplicate and on the same 384-well clear MicroAmp Optical microplate (Invitrogen) and negative controls consisted of a reaction containing an RT negative cDNA sample and a PCR blank containing water. qRT -PCR was performed on the Viia 7 Real-time PCR system (Invitrogen) using default settings for Fast SYBR Green Reagents with the inclusion of a dissociation curve to ensure product specificity. Raw CT values were processed using the DCT method relative to the geometric mean of two reference genes, ACTB and GAPDH. These reference genes have been widely utilized in other studies of choriocarcinoma cell line mRNA expression levels (Lee et al., 2004; Chiu et al., 2007; Li et al., 2008; Masumoto et al., 2011; Mparmpakas et al., 2012; Chen et al., 2013) . DCT values generated relative to ACTB and GAPDH were highly correlated in all assays included in this study (Supplementary data, Fig. S2 ) and all comparisons yielded expression changes in the same direction.
Statistics
A Student's unpaired t-test was used to assess the effect of 5-Aza-CdR exposure compared with vehicle control in BeWo or JEG3 cells on DNA methylation or gene expression outcomes. A Spearman's rank correlation coefficient was used to assess the association between DNA methylation and gene expression at corresponding loci. A Pearson correlation coefficient was calculated to give the correlation for gene expression between two reference genes. A one-way ANOVA with Dunn's post hoc analyses calculated statistical differences in fusion/differentiation markers over three culture time points. P-values , 0.05 were considered significant.
Results
Pilot 5-Aza-CdR studies
To determine the effect of 5-Aza-CdR exposure of placental choriocarcinoma cell lines on cell proliferation and survival, cells were incubated with varying concentrations of 5-Aza-CdR (1-10 mM) and cell viability measured at 24, 48 and 72 h time points. In BeWo cells, cell viability after 48 h treatment was not different from that of 24 h treatment (at any 5-Aza-CdR dose); however, there was a 2-fold decrease in luminescent signal after exposure for 72 h compared with 24 h, particularly at 3, 5 and 10 mM 5-Aza-CdR (P , 0.01; Fig. 1A ). Cell viability was not significantly affected by 5-Aza-CdR exposure in JEG3 cells, with no significant differences in luminescence signal produced between time points for each dose assessed (Fig. 1B) . However, cell survival did appear to be lowered at the 72-h time point, especially at 5 and 10 mM 5-Aza-CdR concentrations (Fig. 1B) . BeWo and JEG3 cells were plated at low density and exposed to 1, 3, 5 and 10 mM 5-Aza-CdR for 48 or 72 h, and then re-plated for a further 72 h. This recovery period was included to ensure the harvest of viable non-apoptotic cells and to demonstrate genuine gene expression changes due to DNA methylation-dependent activities, as opposed to the reversible effects of 5-Aza-CdR-induced toxicity (Palii et al., 2008) . In BeWo cells, the highest 5-Aza-CdR concentration (10 mM) resulted in extensive cell death during the recovery period, and therefore methylation and expression data were unavailable at this dose.
To obtain a broader measure of genomic DNA methylation knockdown, the effect of 5-Aza-CdR exposure was examined by analysis of LINE1 DNA methylation. In untreated BeWo and JEG3 cells, LINE1 methylation levels were 80 and 70%, respectively, which is higher than the 60% observed in chorionic villi at all gestational ages . DNA methylation was significantly reduced at LINE1 genomic repeats at each 5-Aza-CdR dose and time point measured indicating widespread reduction of DNA methylation levels ( Fig. 1C and D) . LINE1 DNA methylation was decreased by 35-40% following 1 mM 5-Aza-CdR for 48 and 72 h in BeWo ( Fig. 1C ; P , 0.01) and JEG3 ( Fig. 1D ; P , 0.01) cells.
DNA methylation levels were also assessed at two gene regions, TEA domain family member 3 (TEAD3) and 3b-hydroxy-delta-5-steroid dehydrogenase type 1 (HSD3B1), previously shown to have reduced methylation in pre-eclampsia, which like the LINE1 data revealed that exposure to 1 mM 5-Aza-CdR for 48 h was sufficient to significantly reduce DNA methylation levels. DNA methylation (mean + SD; %) was decreased .2-fold in BeWo cells treated with 1 mM 5-Aza-CdR for 48 h compared with vehicle controls in the HSD3B1 exon 2 (22.8 + 2.2 versus 46.8 + 2.4; P , 0.001) and TEAD3 intron 1 (41.3 + 1.7 versus 93.1 + 2.3; P , 0.001) region. In JEG3 cells, 1 mM 5-Aza-CdR for 48 h also led to significant decreases in DNA methylation values (mean + SD; %) compared with controls (HSD3B1: 37.7 + 6.9 versus 68.7 + 0.9; P , 0.05 and TEAD3: 39.3 + 1.9 versus 82.4 + 3.4; P , 0.001). Therefore, to minimize exposure to drug toxicity we opted to continue experiments treating both cell lines for 48 h with 1 mM 5-Aza-CdR, followed by a 72 h recovery period.
5-Aza-CdR exposure leads to consistent demethylation of CpG sites at each locus studied
A variable number of CpG sites (between 1 and 12) were assessed across the pyrosequencing assays included in the study (Table I) . In assays containing . 1 CpG site (LEP promoter, CYP19 exon 1.1 promoter, HSD11B2 promoter, TEAD3 intron 1 and NR3C1 exon 1D promoter), DNA methylation was consistently and similarly decreased at each site measured and between each independent experiment (n ¼ 6; Fig. 2 ). Since DNA methylation values were highly correlated with one another (Spearman's correlation all P , 0.05) an average methylation value for that gene region was subsequently analysed.
DNA methylation knock-down has variable effects on gene activation in placental choriocarcinoma cell lines
In untreated choriocarcinoma cells, DNA methylation levels at each locus studied were compared with previously published values obtained from third trimester control placental chorionic villous samples Hogg et al., 2013a, b) . In both BeWo and JEG3 cells, promoter DNA methylation levels for leptin (LEP), inhibin beta A subunit (INHBA) and nuclear receptor subfamily 3, group C, member 1 Figure 2 Within-assay DNA demethylation concordance for multiple CpG sites across experiments. DNA methylation (%) was consistently and similarly decreased at each CpG site measured and across six independent experiments in both BeWo and JEG3 cells at the leptin (LEP) promoter (A and B), CYP19 exon 1.1 promoter (C and D), 11b-hydroxysteroid dehydrogenase type 2 (HSD11B2) promoter (E and F), TEA domain family member 3 (TEAD3) intron 1 (G and H) and nuclear receptor subfamily 3, group C, member 1 (NR3C1) exon 1D promoter (I and J).
however, intronic DNA methylation at TEAD3 was hypermethylated (.80%) compared with chorionic villi (52%; Supplementary data, Fig. S3G ). Exposure of choriocarcinoma cells to 5-Aza-CdR led to significant loss of DNA methylation levels at each gene region studied, by 30-50% points (Figs 3 and 4) . The hypothesized effect on gene expression depended on the region of differential methylation, such that a decrease in DNA methylation at the gene promoter would be associated with an increase in expression, and gene body (exonic or intronic) methylation loss could lead to gene expression changes in either direction. In choriocarcinoma cell lines, the effect of global DNA methylation knock-down was exclusively to activate rather than repress any transcript studied; however, the magnitude of this effect was gene specific.
In BeWo cells, of the transcripts studied, LEP was the most abundantly expressed in response to DNA methylation knock-down with a .200-fold increase in expression in 5-Aza-CdR treated cells compared with vehicle controls ( Fig. 3A ; P , 0.01). A significant negative correlation was observed for LEP mRNA expression and DNA methylation of the LEP promoter (Fig. 3B) . Both CYP11A1 and HSD3B1 transcripts were up-regulated 40-fold, with smaller but significant expression increases noted for CYP19 (5-fold) and HSD11B2 (3-fold) genes ( Fig. 3A; all P , 0.01). The level of each of these transcripts was inversely correlated with DNA methylation values associated with that gene (Fig. 3C -F, respectively) . Expression of TEAD3 in BeWo cells was not significantly changed, despite .50% reduction in DNA methylation within TEAD3 intron 1 (Fig. 3A) , a region previously shown to be differentially methylated in pre-eclampsia. A smaller degree of activation (2 -3-fold) was observed for NR3C1 transcripts in BeWo cells exposed to 5-Aza-CdR (P , 0.01). Nevertheless, DNA methylation of sites proximal to the NR3C1 exon 1D promoter was correlated with expression of each NR3C1 transcript studied (Fig. 3G) .
Similar to the effect in BeWo cells, LEP was highly up-regulated (40-fold) in JEG3 cells exposed to 5-Aza-CdR compared with vehicle controls ( Fig. 4A ; P , 0.01) and there was a positive correlation between mRNA expression and DNA methylation of the LEP promoter (Fig. 4B) . The JEG3 response to DNA methylation knock-down was however modest for most genes studied, with small increases in the expression of CYP11A1, HSD3B1, CYP19, HSD11B2 and INHBA transcripts ( Fig. 4A ; all P , 0.05). However, with the exception of HSD3B1 (Fig. 4D ), significant correlations were observed for expression and DNA methylation of CYP11A1, CYP19, HSD11B2 and INHBA genes (Fig. 4C , E-G, respectively). Expression of TEAD3 and NR3C1 transcripts was not significantly altered by DNA methylation knock-down in JEG3 cells (Fig. 4A) .
Discussion
The aim of this study was to establish an in vitro placental model of DNA methylation knock-down to (i) provide mechanistic evidence to support associative findings from our previous studies relating to pre-eclampsia and to (ii) determine the degree of transcriptional response to altering DNA methylation levels across a panel of genes related to endocrine signalling in the placenta.
Previously, we observed DNA methylation changes at candidate genes involved in hormone availability, signalling and synthesis in placentae associated with early onset pre-eclampsia (Hogg et al., 2013a, b) . In a subset of placental samples, we measured mRNA expression levels corresponding to the locus in question, and detected significant associations between DNA methylation and RNA expression in some cases; however, the issues of RNA degradation and inconsistent placenta processing time due to the nature of the study were a limitation. To overcome this is issue we aimed to use an in vitro placental model to assess the genome-wide effect of DNA methylation loss on gene expression.
Effective knock-down of DNA methylation was achieved in both BeWo and JEG3 choriocarcinoma cells through exposure to the DNMT1 inhibitor 5-Aza-CdR, with a reduction in DNA methylation levels of 30 -50% after 48 h exposure at all sites studied. However, the transcriptional response to loss of associated DNA methylation marks was variable. While gene expression at some loci was highly affected, more modest or absent changes in gene levels were observed at others.
Of our candidate genes, LEP (encoding leptin) was the most abundantly up-regulated following DNA methylation knock-down in both BeWo (.200-fold) and JEG3 (.40-fold) cells. In addition to an adiposederived role in metabolic homeostasis (Zhang et al., 2005) , leptin is synthesized and secreted by the placental trophoblast cells, and has roles in embryo development, implantation, placental hormone regulation and trophoblast survival (Henson and Castracane, 2006; Gambino et al., 2012) . Furthermore, leptin is up-regulated in the placenta (Laivuori et al., 2006; Hoegh et al., 2010; Blair et al., 2013) and elevated in the plasma (Chappell et al., 2002; Molvarec et al., 2011; Hogg et al., 2013b) of women with pre-eclampsia.
The LEP gene is associated with a tissue-specific differentially methylated promoter contained within a CpG island (Melzner et al., 2002; Stoger 2006 ). An inverse correlation between promoter methylation and LEP expression was demonstrated in pre-adipocytes, adipocytes and liver (Melzner et al., 2002; Marchi et al., 2011) . In the placenta, we have shown that DNA methylation of the LEP promoter is lowered in early onset pre-eclampsia-associated placentae, and placental DNA methylation and maternal plasma leptin concentrations were correlated, albeit weakly (Hogg et al., 2013b ). In the current study, there was a strong relationship between LEP promoter DNA methylation levels and gene expression in placental cell lines. These data support a role for DNA methylation regulation, or at least a robust marker, of LEP expression in the placenta, without the caveat of RNA/protein degradation of clinical samples.
Genes related to steroid hormone synthesis in the placenta were also profiled. Our previous work suggested the involvement of DNA methylation in the regulation of genes encoding steroidogenic pathway enzymes, including CYP11A1, encoding P450 side-chain cleavage, and HSD3B1, encoding 3b-hydroxy-delta-5-steroid dehydrogenase type 1, both enzymes that are necessary for the production of progesterone and estrogen. In early onset pre-eclampsia, hypomethylation by ≥10% points at CpG sites at both CYP11A1 and HSD3B1 gene regions was associated with significant and correlative increases in the corresponding placental transcript levels (Hogg et al., 2013a ). In the current study, functional data derived from DNA methylation knock-down in BeWo cells closely mirrored our previous findings in placenta, demonstrating a robust up-regulation of both CYP11A1 and HSD3B1 in response to 5-Aza-CdR exposure. The expression of TEAD3, encoding a placentalspecific transcription factor required for the transactivation of HSD3B1 (Peng et al., 2004) , was also studied in the DNA methylation-depleted placental cell lines. We found no change in TEAD3 expression in BeWo or JEG3 cells in vitro despite global DNA methylation knock-down. Likewise, in early onset pre-eclampsia, while DNA methylation was reduced Figure 3 The effect of DNA methylation knock-down in BeWo cells on gene activation. (A) DNA methylation levels (%) and corresponding mRNA levels of associated transcript/s (fold change relative to control) are presented on the right and left panel, respectively. BeWo cells were cultured for 48 h in media containing vehicle only (vehicle control; grey bars) or 1 mM 5-Aza-CdR (black bars). Data are mean + SD of six independent experiments and P-values are represented by *P , 0.05, **P , 0.01 and ***P , 0.001. (B -G) Spearman's rho (R) was calculated for the correlation between DNA methylation (%) and associated mRNA transcript (absolute values relative to the geometric mean of GAPDH and ACTB reference genes) across control and 5-Aza-CdR-exposed BeWo cells. LEP: leptin, HSD3B1: 3b-hydroxy-delta-5-steroid dehydrogenase type 1, HSD11B2: 11b-hydroxysteroid dehydrogenase type 2, TEAD3: TEA domain family member 3, NR3C1: nuclear receptor subfamily 3, group C, member 1.
by 20% points at an intronic region of TEAD3, we found no corresponding change in placental TEAD3 transcript levels (Hogg et al., 2013a) .
In the placenta, the conversion of steroid precursors into estrogen requires the enzymatic action of aromatase, encoded by CYP19. In steroidogenic tissues, CYP19 expression is activated at tissue-specific promoters: namely CYP19 exon 1.1 in the placenta (Mendelson and Kamat, 2007) . Hypomethylation at exon 1.1 concomitant with up-regulated placental CYP19 mRNA was previously associated with early onset pre-eclampsia, yet the association with DNA methylation was slight (Hogg et al., 2013a) . In this study, a moderate and correlative increase in CYP19 expression was found in placental choriocarcinoma cell lines following DNA methylation depletion. Other studies do Figure 4 The effect of DNA methylation knock-down in JEG3 cells on gene activation. (A) DNA methylation levels (%) and corresponding mRNA levels of associated transcript/s (fold change relative to control) are presented on the right and left panel, respectively. JEG3 cells were cultured for 48 h in mediacontaining vehicle only (vehicle control; grey bars) or 1 mM 5-Aza-CdR (black bars). Data are mean + SD of six independent experiments and P-values are represented by *P , 0.05, **P , 0.01 and ***P , 0.001. (B -G) Spearman's rho (R) was calculated for the correlation between DNA methylation (%) and associated mRNA transcript (absolute values relative to the geometric mean of GAPDH and ACTB reference genes) across control and 5-Aza-CdR exposed JEG3 cells. LEP: leptin, HSD3B1: 3b-hydroxy-delta-5-steroid dehydrogenase type 1, HSD11B2: 11b-hydroxysteroid dehydrogenase type 2, INHBA: inhibin beta A subunit, TEAD3: TEA domain family member 3, NR3C1: nuclear receptor subfamily 3, group C, member 1.
suggest some involvement of promoter and tissue-specific DNA methylation in human CYP19 expression, for example in skin fibroblasts (Demura and Bulun, 2008) and breast adipose fibroblasts (Knower et al., 2010 ) that may interfere with transcription factor-binding potential (Demura and Bulun, 2008) .
Multiple signalling pathways play a role in the expression of HSD11B2 in the placenta (Pasquarette et al., 1996; Alikhani-Koopaei et al., 2004; Sharma et al., 2009; Li et al., 2011; Guan et al., 2013) . Both pre-eclampsia (Schoof et al., 2001) and intrauterine growth restriction (IUGR) (Dy et al., 2008) are associated with decreased placental HSD11B2 mRNA and protein activity. While other studies report an association with placental DNA methylation of the HSD11B2 promoter and low birthweight (Marsit et al., 2012) , we previously found no such association in either IUGR or pre-eclampsia cases (Hogg et al., 2013a) . In the present study there was a 3-fold increase in HSD11B2 expression following global DNA methylation knock-down in BeWo and JEG3 cells. Other groups have also reported HSD11B2 activation following 5-Aza-CdR exposure in JEG3 cells (Alikhani-Koopaei et al., 2004) . Additionally, recent evidence using primary term cytotrophoblasts suggests that acetylation and methylation of associated histone marks in response to cAMP-induced Sp1 binding is also relevant to HSD11B2 expression in the placenta (Li et al., 2011) .
The glucocorticoid receptor gene, encoded by NR3C1, is widely studied in the context of the developmental programming of health and disease (Weaver et al., 2004 (Weaver et al., , 2007 Oberlander et al., 2008; McGowan et al., 2009; Radtke et al., 2011) and consists of a number of tissue-specific alternative promoters that are contained within a CpG island (Turner and Muller 2005; Cao-Lei et al., 2011) . Few studies have examined the role of DNA methylation at the NR3C1 promoter in the placenta. A link between placental NR3C1 exon 1F DNA methylation and infant neurobehaviour in uncomplicated pregnancy (Bromer et al., 2013) and in babies born large for gestational age (Filiberto et al., 2011) has been reported. However, changes in exon 1F DNA methylation levels were small (1-5% points) and functional placental expression data were not provided.
We recently showed that in healthy third trimester placentae, the NR3C1 promoter region was generally unmethylated (,10%), with the exception of exon 1D where methylation values ranged from 5 to 40% in the normal population. In early onset pre-eclampsia, mean DNA methylation values were significantly increased by 9% points at exon 1D compared with healthy controls, and not affected elsewhere in the promoter region (Hogg et al., 2013a ). While we were previously able to measure total NR3C1 mRNA using a microarray platform (which showed no change between controls and cases) we were unable to directly measure exon 1D transcript levels to determine a functional link with DNA methylation status. In the current study, there was a small and similar increase in total NR3C1, exon 1C (predominantly expressed) and exon 1D transcripts in BeWo cells exposed to 5-Aza-CdR, which was correlated with DNA methylation values proximal to exon 1D. In JEG3 cells, the expression of NR3C1 transcripts was unaffected and not correlated with associated DNA methylation values. These data combined with our previous work indicate only a minor role for promoter DNA methylation regulation of NR3C1 in the placenta, and suggest that in clinical cases differential DNA methylation within the promoter region should be interpreted with caution. However, we cannot exclude that DNA methylation at any upstream or downstream regulatory elements might play a role in NR3C1 regulation.
Finally, we studied the effect of DNA methylation knock-down on the expression of INHBA in vitro. INHBA mRNA was undetectable in BeWo cells, but expressed in and up-regulated 3-fold in JEG3 cells exposed to 5-Aza-CdR. In vivo, we previously observed decreased placental DNA methylation of 20% points at the INHBA promoter in preeclampsia, as well as a non-significant trend towards increased gene expression . Other studies have found INHBA mRNA to be significantly up-regulated in pre-eclampsia-associated placentae (Enquobahrie et al., 2008; Hoegh et al., 2010) and an elevation of inhibin A in maternal plasma of women with pre-eclampsia (Bersinger et al., 2003; Salomon et al., 2003) . Thus, these in vitro and in vivo data point towards DNA methylation as a potential contributor to the elevated INHBA/inhibin A observed in pre-eclampsia.
We did not use primary placental cells in this study, since primary villous cytotrophoblasts do not proliferate and spontaneously differentiate after 48 h in culture. The advantage of using placental-derived cell lines over primary cells is their proliferative capacity allowing for effective DNA methylation knock-down using the 5-Aza-CdR compound, which requires two rounds of replication to fully de-methylate the DNA strand (Christman, 2002) .
We selected only genes previously shown to exhibit altered DNA methylation in pre-eclampsia-placentae in order to provide functional evidence for earlier in vivo studies. In this study, DNA methylation depletion in BeWo and JEG3 cell lines exerted loci-specific effects on gene activation. However, it is likely that a number of genes are in fact repressed by global loss of DNA methylation, indirectly by changes to transcription factor expression or directly at the chromatin level (Guenard et al., 2013; Ito et al., 2013) , or show no correlation with promoter DNA methylation levels at all (Carone et al., 2010) . We also acknowledge that by globally reducing DNA methylation, it is not possible to directly link DNA methylation and gene expression at the specific CpG sites studied, due to other CpG sites in the gene body, promoter or enhancer regions, also being affected. Nevertheless, it is interesting that most of the loci studied were up-regulated in conjunction with the loss of placental DNA methylation at the sites for which we have previously observed altered methylation in pre-eclampsia, and that the degree to which this occurred was highly variable.
Expression of the LEP gene was significantly up-regulated by DNA methylation loss, which is supportive of a role for promoter DNA methylation as a regulator, or at least as an indicator, of LEP expression in the placenta. Steroidogenic genes, including CYP11A1 and HSD3B1, were also abundantly up-regulated in response to DNA methylation knockdown. Relatively, gene activation at other candidate genes including CYP19, HSD11B2 and INHBA was more moderate, but nonetheless correlated with associated DNA methylation values. Despite being contained within a CpG island, NR3C1 exon 1D methylation levels were weakly associated with transcript expression.
Many factors may affect gene expression, of which DNA methylation may be just one component of the regulatory process. Therefore, more loci-specific functional work is required to clarify the relationship between DNA methylation at these selected sites and gene activity in the placenta. Nevertheless, these data suggest that in the human placenta, altered DNA methylation levels may represent highly variable effects on gene expression outcomes. Accordingly, DNA methylation changes should be interpreted with caution in relation to transcript expression in the absence of accompanying functional evidence.
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